Health Care • Biotechnology: Pharmaceutical Preparations
$23.80 ▼ -0.23
(-0.96%)
MKT CAP: $782.3M • VOL: 402.0K
52W L $21 52W H $51
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$20
MEDIAN
$27
MEAN
$27
HIGH
$32
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE COLL TAPE
COLL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $28.80 | $27.37 | 2025-02-14 | $21.66 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $29.99 | $28.08 | 2025-02-06 | $22.37 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $27.13 | $26.18 | 2025-01-29 | $22.85 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $24.28 | — | 2025-01-17 | $23.32 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $20.94 | $22.61 | 2025-01-09 | $21.18 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $28.32 | $24.75 | 2024-12-18 | $20.71 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $23.09 | $24.04 | 2024-12-04 | $22.13 | -4.3% | 48% | C |